SCHEMBL10201259

SCHEMBL10201259

CCc1cc(-c2sc(C(=O)Nc3ccccc3F)cc2F)n(CC)n1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 6/20 0.51
RAB9A P51151 3/20 0.51
NPC1 O15118 2/20 0.51
TSHR P16473 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51
KDM4E B2RXH2 1/20 0.44
TP53 P04637 2/20 0.41
KMT2A Q03164 4/20 0.41
MAPT P10636 4/20 0.41
MEN1 O00255 3/20 0.41
MAPK1 P28482 1/20 0.41
STIM1 Q13586 2/20 0.41
ORAI1 Q96D31 2/20 0.41
HTT P42858 1/20 0.40
ESR1 P03372 1/20 0.39
ESRRG P62508 1/20 0.39
RIPK1 Q13546 1/20 0.39
NR1I2 O75469 1/20 0.38
ALDH1A1 P00352 1/20 0.38
AHR P35869 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10201258 0.91 NPC1 (0.45) SMN1; SMN2RAB9ANPC1TSHRNPSR1
SCHEMBL10201251 0.91 SMN1; SMN2 (0.48) SMN1; SMN2RAB9ANPC1TSHRNPSR1
SCHEMBL10201262 0.88 STIM1 (0.40) SMN1; SMN2RAB9ANPC1TSHRNPSR1
SCHEMBL10201248 0.88 SMN1; SMN2 (0.47) SMN1; SMN2RAB9ANPC1TSHRNPSR1
SCHEMBL10201234 0.87 STIM1 (0.48) SMN1; SMN2RAB9ANPC1TSHRNPSR1
SCHEMBL10201245 0.80 STIM1 (0.38) SMN1; SMN2RAB9ANPC1TSHRNPSR1
SCHEMBL10201261 0.79 NPC1 (0.45) SMN1; SMN2RAB9ANPC1TSHRKDM4E
SCHEMBL10201235 0.79 STIM1 (0.46) SMN1; SMN2RAB9ANPC1TSHRNPSR1
SCHEMBL10201229 0.79 STIM1 (0.54) SMN1; SMN2RAB9ANPC1TSHRNPSR1
SCHEMBL10201247 0.77 STIM1 (0.38) SMN1; SMN2RAB9ANPC1TSHRNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10336738-B2 Compounds that modulate intracellular calcium CALCIMEDICA, INC. (US) 2019-07-02 US disclosed
US-20150344469-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM AVENUE CAPITAL MANAGEMENT II, L.P. 2015-12-03 US disclosed
US-20150344469-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM AVENUE CAPITAL MANAGEMENT II, L.P. 2015-12-03 US disclosed
US-9079891-B2 Compounds that modulate intracellular calcium CALCIMEDICA, INC. (US) 2015-07-14 US disclosed
US-9079891-B2 Compounds that modulate intracellular calcium CALCIMEDICA, INC. (US) 2015-07-14 US disclosed
WO-2012027710-A2 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM CALCIMEDICA INC. (US) 2012-03-01 WO disclosed
US-20120053210-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM CALCIMEDICA, INC. (US) 2012-03-01 US disclosed
US-20120053210-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM CALCIMEDICA, INC. (US) 2012-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10336738-B2 Compounds that modulate intracellular calcium ORAI1, SARAF, RYR2 SMN1; SMN2 854/4885RAB9A 1174/4885NPC1 262/4885
US-20150344469-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM ORAI1, SARAF, RYR2 SMN1; SMN2 854/4885RAB9A 1174/4885NPC1 262/4885
US-20120053210-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM ORAI1, SARAF, RYR2 SMN1; SMN2 854/4885RAB9A 1174/4885NPC1 262/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.